The 2019 novel coronavirus (nCoV) pandemic is rapidly developing across the globe and new information is emerging expeditiously and constantly, particularly in relation to neurological illnesses. Both central and peripheral nervous system involvement has been reported including headache, dizziness, hyposmia/anosmia, taste disturbances, seizures, stroke, alteration of the sensorium, and even acute hemorrhagic necrotizing leukoencephalopathy. Varying degrees of olfactory disturbances may pre-empt the diagnosis of COVID-19. Although no direct effect of 2019 nCoV has been reported yet on Parkinson’s disease, there are enormous possible indirect effects and implications. We examine the potential effects and challenges posed by this pandemic to individuals with Parkinson’s disease, particularly in the Indian context where telecommunication access or support group access may be lacking for these patients. Additionally, lockdown and social distancing may pose hurdles in the provision of optimum medical therapy, particularly if patients experience motor and non-motor deteriorations due to diverse reasons.

Keywords: COVID-19, India, movement disorders, Parkinson’s disease
respiration and cardiovascular tone, and also, from the point of view of movement disorders, the striatal circuitry.\[^{10}\] To date, a direct effect on the nigrostriatal pathway is not known, but considering an example from the H1N1 influenza virus, may be plausible. The Movement Disorders Society has recently published recommendations and priorities for patients with movement disorders during the COVID-19 pandemic.\[^{11,12}\] From India, a case series of 21 patients have been recently published. Most (67%) of patients were males and in the 21–40 years age group. Although neurological features have not been focused on in this series, one person each had migraine, anxiety and obstructive sleep apnea.\[^{13}\] Against this background, we explore the potential impact of the 2019-nCoV on patients with PD, particularly from an Indian perspective.

**Burden of overlap**

In 2016, it was estimated that 6.1 million people worldwide had PD. The prevalence in India was roughly 10% of the global burden, that is, 5.8 lakhs.\[^{14}\] From India, crude prevalence rates (CPR) between 6 and 53/100,000 have been reported. Above the age of 60 years, the PRs were higher, being 247/100,000.\[^{15}\] It is known to occur in 1% of people above the age of 65 years. As per WHO estimates, the highest mortality in COVID-19 is among older individuals, with the highest death rates in those above the age of 80 years. It is, therefore, reasonable to conclude that persons with PD affected by the COVID-19 pandemic in India form a particularly high-risk population since most PD patients are above the age of 60 years. There is also the possibility that stress, especially high during these times, unmasks latent PD.\[^{16}\] Whether there is an increase in the incidence or prevalence of PD following the pandemic will only be answered by long-term longitudinal studies.

**Lessons from the past**

The 1918 Spanish flu pandemic was caused by H1N1 influenza A, post-encephalitic parkinsonism or encephalitis lethargica followed this pandemic and was believed to be of viral etiology, likely enterovirus.\[^{17}\] Neurological features, albeit not parkinsonism, were reported following the SARS and MERS outbreaks.\[^{18}\] Even in the current pandemic, smell impairment is reported in 5–7% of patients.\[^{19}\] The fact that anosmia may precede overt alpha-synucleinopathies and is a premotor feature may suggest potential overlap between PD and COVID-19.\[^{19}\]

**Predisposing factors in PD**

Persons with PD have significantly associated comorbidities including cardiac failure, coronary artery disease, cerebrovascular disease, diabetes all of which predispose to more severe forms of the COVID-19.\[^{20}\] Additionally, both persons with PD as well as higher mortality groups among those afflicted with COVID-19 have larger male proportions.\[^{21-23}\] Another contributory factor may be that the immune response in PD may be disrupted and this may also predispose this population to COVID-19. Microglia play an immune surveillance role and are mediators of the innate immune response.\[^{24}\] Immune disbalance, triggered by putative infectious agents, may play a role in pathogenesis in PD.

**Exacerbations due to intercurrent illness**

In general, both motor and non-motor symptoms of PD may be exacerbated by intercurrent infections including viral infections. Patients may experience deterioration of bradykinesia, rigidity as well as tremor following systemic infection. Possible mechanisms that underlie these exacerbations include altered brain metabolism of dopamine, changes in drug pharmacodynamics or effects of inflammatory changes secondary to infections or the direct effect of endotoxins triggered by the infectious agent.\[^{25}\]

As a result, persons with PD infected with SARS-CoV-2 are likely to have a motor and non-motor deterioration. Clinicians must assess these patients for worsening in PD from baseline status and up-titrating the dopaminergic drugs as necessary. Motor deterioration may be in terms of both the cardinal features (tremor, rigidity and bradykinesia) but also falls. Non-motor worsening may include sleep disturbances, anxiety, and depression.

**Ventilatory issues**

Severe respiratory issues occur in COVID-19 which may necessitate ventilation. This is an important factor to consider because persons with PD already have some form of restrictive lung disease, characterized by respiratory muscle bradykinesia, rigidity and dystonia of the trunk. Loss of chest wall compliance may occur due to camptocormia. Even a severe obstructive pattern of airflow has been reported in advanced PD.\[^{26}\] Dystonia of the neck may make intubation challenging. Per se, dyspnea is also reported by persons with PD and is considered to be an underestimated symptom, which may be associated with motor fluctuations or even anxiety.\[^{27}\]

Additionally, the COVID-19 virus has the potential to inhibit cough reflex and potentiate swallowing dysfunction in these patients, predisposing them to aspiration and aspiration pneumonia.

**Drug-related issues**

The interactions between drugs used for PD and coronavirus are unclear. We do not know whether the drugs used in PD management could have an impact on the virus. Conversely, whether the virus will influence drug effects is also not known. Foremost among PD drugs is the potential role of amantadine. Amantadine was used in the management of the influenza A virus. It acts by interfering with virus uncoating inside the cell. It blocks the M2-protein which forms an ion channel on the viral membrane which is required for virus transport inside the cell. However, its use was associated with the emergence of drug-resistant mutants and hence, it is no longer favored for this indication. Whether this drug blocks a protein on the 2019 novel coronavirus is not clear although this has been previously reported for the SARS coronavirus.\[^{28}\]

Another concern relevant to drugs is their administration in a PD patient who is ventilated for COVID-19. Oral drug administration in this condition would be via nasogastric tube of a percutaneous enterostomy tube. Options to maintain
smooth dopaminergic drugs and avoid dopaminergic withdrawal states in such a situation include liquid levodopa, transdermal rotigotine patches as well as apomorphine subcutaneous intermittent injections or apomorphine pump. In India, the option of apomorphine is available although costly.

**Psychological aspects**

Half of the patients with PD experience fatigue.[29] Dopamine depletion in the nigrostriatal pathway has been associated with motor and cognitive inflexibility in PD patients.[30] A role of dopamine has also been hypothesized in optimal coping mechanisms, the depletion of which may lead to increased stress and a sense of loss of control in PD patients.[31] Hence, almost 40–50% also have clinically significant anxiety and depression[32] which may further worsen, either on receiving a diagnosis of COVID-19, or even self-isolation. These issues comprise ‘hidden sorrows’ in PD patients.[33] Post-viral asthenia may exacerbate fatigue. Increased stress in these patients may not only exacerbate motor symptoms such as dyskinesias and freezing of gait but also reduced the efficacy of dopaminergic medications.[34] This may even lead to uncovering of a latent akinetic-rigid state.[35] PD patients should be encouraged to join peer support groups via social media services as well as various societies so that they may be able to interact with other peers during these trying times. These strategies may encourage PD patients to be resilient even in times of crisis.

**Rehabilitation**

As a result of social distancing, immobilization, and lockdowns necessitated by COVID-19, exercise, as well as physiotherapy or other rehabilitative services, maybe interrupted for PD patients. This lack of physical activity may lead to a worsening in the motor as well as non-motor symptoms such as constipation. Patients should be advised to follow a light yoga program at home and maintain stretching and exercises that they would have been encouraged to learn earlier. The recent Park-in-Shape trial showed that home-based aerobic activity (30–45 min of stationary cycling using a home trainer thrice weekly over 6 months) compared to stretching may help attenuate the off-state motor signs in PD patients and may be encouraged.[36] Mindfulness strategies are known to reduce depression and anxiety levels.[37] Such home-based exercised and relaxation techniques may promote coping during the lockdown period. Many mindfulness applications may be used for practice. These programs may be accessed via applications on smartphones or online platforms.

**Providing medical advice during COVID-19 times**

The social distancing norms that have found widespread advent in these times pose enormous challenges to medical consultation and it is the need of the hour for clinicians as well as patients to be well versed with teleconsultation/video consultation techniques. There are obvious disadvantages including lack of patient proximity for examination as well as an inability to manage some problems such as deep brain stimulation device-related issues. Nevertheless, valuable advice, as well as medical support, can be provided to PD patients using these services. The challenges to these solutions in India are obviously, lack of awareness or access to telecommunication methods. Additionally, there may be medicolegal concerns about advice delivered through these mechanisms although guidelines are in place to safeguard against the same.

Persons with PD may hence not only be a vulnerable population in COVID-19 times but also a high-risk population. Such patients must be encouraged to particularly follow the principles of hand hygiene and social distancing while simultaneously organizing social support groups and medical access via telecommunication services. This would prevent these persons, already isolated by the disease to some extent, from further feeling isolated and bereft of medical support.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
3. Tsai LK, Hsieh ST, Chao CC, Chen YC, Lin YH, Chang SC, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 2004;61:1669-73.
4. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): A report from China. J Pathol 2003;200:282-9.
5. Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: Report of A case. Acta Neurol Taiwan 2006;15:26-8.
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized Patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020. doi: 10.1001/jamaneurol.2020.1127.
7. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated Acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020:201187. doi: 10.1148/radiol. 202021187.
8. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020. doi: 10.1002/jmv. 25728.
9. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv. 2020. doi: 10.1101/2020.01.26.919985.
10. Dobay MF, Talman LS, Obr TD, Tian X, Davission RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007;292:R373-81.
11. Papa SM, Brundin P, Fang VSC, Kang UJ, Burn DJ, Colosimo C, et al. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders. Mov Disord 2020. doi: 10.1002/mds.28067.
12. Stoessl AJ, Bhatia KP, Merello M. Editorial: Movement disorders in the world of COVID-19. Mov Disord 2020. doi: 10.1002/mds.28069.
13. Gupta N, Agrawal S, Ish P, Mishra S, Gaind R, Usha G, et al. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. Monaldi Chest Dis 2020:90:193-6.
14. Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson’s disease,
1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17:939–53.
15. Razdan S, Kaul RL, Motta A, Kaul S, Bhatt RK. Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986. Neuroepidemiology 1994;13:113–9.
16. Djamshidian A, Lees AJ. Can stress trigger Parkinson’s disease? J Neurol Neurosurg Psychiatry 2014;85:878–81.
17. Dourmasdkin RR, Dunn G, Castano V, McCall SA. Evidence for an enterovirus as the cause of encephalitis lethargica. BMC Infect Dis 2012;12:136.
18. Kim JE, Heo JH, Kim H, Song SH, Park SS, Park TH, et al. Neurological Complications during treatment of Middle East respiratory syndrome. J Clin Neurol 2017;13:227–33.
19. Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis 2018;109:226–48.
20. Wang X, Zeng F, Jin WS, Zhu C, Wang QH, Bu XL, et al. Comorbidity burden of patients with Parkinson’s disease and Parkinsonism between 2003 and 2012: A multicentre, nationwide, retrospective study in China. Sci Rep 2017;7:1671.
21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. doi: 10.1056/NEJMoa2002032.
22. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
23. Huang C, Wang Y, Li X, Ren L, Zhao J, Yi H, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
24. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson’s disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37:510–8.
25. Brugger F, Erro R, Balint B, Kägi G, Barone P, Bhatia KP. Why is there motor deterioration in Parkinson’s disease during systemic infections—a hypothetical view. NPJ Parkinson’s Dis 2015;1:1–5.
26. Baille G, De Jesus AM, Perez T, Devos D, Dujardin K, Charley CM, et al. Ventilatory dysfunction in Parkinson’s disease. J Parkinsons Dis 2016;6:463–71.
27. Baille G, Chenivesse C, Perez T, Machuron F, Dujardin K, Devos D, et al. Dyspnea: An underestimated symptom in Parkinson’s disease. Parkinsonism Relat Disord 2019;60:162–6.
28. Torres J, Maheswari U, Parthasarathy K, Ng L, Liu DX, Gong X. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci 2007;16:2065–71.
29. Siciliano M, Trojano L, Santangelo G, De Micco R, Tedeschi G, Tessitore A. Fatigue in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 2018;33:1712–3.
30. Robbins TW, Cools R. Cognitive deficits in Parkinson’s disease: A cognitive neuroscience perspective. Mov Disord 2014;29:597–607.
31. Douma EH, de Kloet ER. Stress-induced plasticity and functioning of ventral tegmental dopamine neurons. Neurosci Biobehav Rev 2020;108:48–77.
32. Marsh L. Depression and Parkinson’s disease: Current knowledge. Curr Neurol Neurosci Rep 2013;13:409.
33. Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. J Parkinsons Dis 2020;10:351–4.
34. Zach H, Dirix MF, Pasman JW, Bloem BR, Helmich RC. Cognitive stress reduces the effect of levodopa on Parkinson’s resting tremor. CNS Neurosci Ther 2017;23:209–15.
35. Kolk NM van der, Vries NM de, Kessels RPC, Joosten H, Zwijnderman AH, Post B, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: A double-blind, randomised controlled trial. Lancet Neurol 2019;18:998–1008.
36. Kwok JYY, Kwan JCY, Auyeung M, Mok VCT, Lau CKY, Choi KC, et al. Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: A randomized clinical trial. JAMA Neurol 2019;76:755–63.